Technical analysis of DexCom, Inc. (DXCM): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners.
Price Performance
| 1 month | -3.60% |
| 3 months | -5.75% |
| Year-to-date | +23.99% |
| 1 year | +41.34% |
| 3 years | -12.15% |
| 5 years | -48.54% |
| 10 years | +447.87% |
52-Week Range
| 52-week High | $92.59 |
| 52-week Low | $54.11 |
| Avg Volume (90d) | 4.5M |
Technical Indicators
| SMA 50 | $85.82 |
| SMA 200 | $74.56 |
| Beta | 1.56 |
| 30-day Volatility (annualised) | 32.4% |
| Price vs SMA 50 | -4.1% |
| Price vs SMA 200 | +10.4% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $66.37 | |
| 2026-01 | $73.04 | +10.0% |
| 2026-02 | $73.43 | +0.5% |
| 2026-03 | $62.80 | -14.5% |
| 2026-04 | $59.55 | -5.2% |
| 2026-05 | $73.74 | +23.8% |
| 2026-06 | $67.35 | -8.7% |
| 2026-07 | $83.45 | +23.9% |
| 2026-08 | $91.06 | +9.1% |
| 2026-09 | $86.29 | -5.2% |
| 2026-10 | $82.29 | -4.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2027-02-11 | $0.73 | $1.39B |
| 2026-10-29 | $0.68 | $1.33B |
| 2026-07-30 | $0.61 | $1.29B |
| 2026-04-30 | $0.47 | $1.17B |
| 2026-02-12 | $0.65 | $1.25B |
| 2025-10-30 | $0.58 | $1.18B |
| 2025-07-30 | $0.44 | $1.12B |
Price
| Price | $82.29 (closing price, October 30, 2026) |
| Market Cap | $30.7B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 32.27 |
| Price / Book | 12.16 |
| EV / EBITDA | 20.07 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.55 |
| Current Ratio | 1.74 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 6.43 |